| Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979) |
|---|
| 07/27/2005 | CN1646540A Functionalized ionic liquids, and methods of use thereof |
| 07/27/2005 | CN1646520A 1, 3, 5-triazine derivatives as ligands for human adenosine-A3 receptors |
| 07/27/2005 | CN1646519A N-oxyde of N-phenyl-2-pyrimidine-amine derivatives |
| 07/27/2005 | CN1646502A Triazole derivatives as tachykinin receptor antagonists |
| 07/27/2005 | CN1646499A Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| 07/27/2005 | CN1646497A New aryl imidazoles and related compounds as C5a receptor modulators |
| 07/27/2005 | CN1646495A Amine compounds and use thereof |
| 07/27/2005 | CN1646489A Delta1-pyrrolines and their use as pestcidal |
| 07/27/2005 | CN1646446A Non-heating clay composites for building materials |
| 07/27/2005 | CN1646130A Treatment of rheumatoid arthritis |
| 07/27/2005 | CN1212317C Novel ester or amide derivatives |
| 07/26/2005 | US6921821 Antagonists of melanin concentrating hormone receptor |
| 07/26/2005 | US6921764 Treating neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders. |
| 07/26/2005 | US6921762 Substituted indolizine-like compounds and methods of use |
| 07/26/2005 | US6921761 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 07/26/2005 | CA2256609C 5-aroylpyrrol-2-ylmethylarene derivatives as inhibitors of prostaglandin g/h synthase |
| 07/26/2005 | CA2193388C Aryl and heteroaryl alkoxynaphthalene derivatives |
| 07/26/2005 | CA2175498C Phenylindole compounds |
| 07/26/2005 | CA2137623C Phenyl-substituted 1,4-dihydropyridines |
| 07/21/2005 | WO2005066164A1 Opioid receptor antagonists |
| 07/21/2005 | WO2005066162A1 Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer |
| 07/21/2005 | WO2005066159A1 Cathepsin cysteine protease inhibitors |
| 07/21/2005 | WO2005066156A1 Selective kinase inhibitors |
| 07/21/2005 | WO2005066155A1 5-fluoro-, chloro- and cyano-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5 |
| 07/21/2005 | WO2005066154A2 Polymorphs of 1-cyclopropyl-6-fuoro-8-methoxy-7-(4-amino-3, 3-dimethylpiperidin-1-yl) -1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride and mesalyte salts |
| 07/21/2005 | WO2005066151A2 Histone deacetylase inhibitors |
| 07/21/2005 | WO2005066144A1 Morpholine derivatives as norepinephrine reuptake inhibitors |
| 07/21/2005 | WO2005066139A2 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases |
| 07/21/2005 | WO2005066137A1 2,5-diaryl-1h-imidazole-4-carboxamides as neurokinin-3 receptor modulators for the treatment of central nervous system and peripheral diseases |
| 07/21/2005 | WO2005066132A1 Therapeutic agents i |
| 07/21/2005 | WO2005066129A2 Bis-pyridino containing compounds for use in the treatment of cns pathologies |
| 07/21/2005 | WO2005066128A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 07/21/2005 | WO2005066126A1 Cb1 modulator compounds |
| 07/21/2005 | WO2005065779A1 Calcitonin gene related peptide receptor antagonists |
| 07/21/2005 | WO2005065681A1 N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer |
| 07/21/2005 | WO2005065195A2 Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| 07/21/2005 | WO2005065192A2 Photolabile compounds |
| 07/21/2005 | WO2005065183A2 Mitotic kinesin inhibitors |
| 07/21/2005 | WO2005047278A3 Substituted dihydroquinazolines ii |
| 07/21/2005 | WO2005043124A3 Chiral 1,8-diarylnaphthalenes, methods of making them, and their use as sensors |
| 07/21/2005 | WO2005042497A3 Benzimidazoles useful as modulators of ion channels |
| 07/21/2005 | WO2005030979A3 Dark quenchers for fluorescence resonance energy transfer (fret) in bioassays |
| 07/21/2005 | WO2005028452A9 Substituted triazole derivatives as oxytocin antagonists |
| 07/21/2005 | WO2005013914A3 Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| 07/21/2005 | WO2004087051A3 Ophthalmic compositions for treating ocular hypertension |
| 07/21/2005 | WO2004056804A8 Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates |
| 07/21/2005 | WO2004055004A8 Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators |
| 07/21/2005 | US20050159601 Ligands and catalyst systems thereof for ethylene oligomerisation to linear alpha olefins |
| 07/21/2005 | US20050159599 Insecticides for soil/seed treatment |
| 07/21/2005 | US20050159585 Forming acyl azide function on acid group of amino acid derivative, then transforming to isocyanate |
| 07/21/2005 | US20050159584 O-succinimidyl-2-[(9H-fluoren-9-ylmethoxy)carbonylamino]-ethylcarbamate's used as monomers active in the synthesis of di- and tri-substituted ureas and urea oligomers |
| 07/21/2005 | US20050159475 Making intermediates to alpha-ethyl-2-oxo-1-pyrrolidine acetamide, also referred to as levetiracetam an antihypoxic agent and antiischemic agent; by reduction via catalytic hydrogenation of an alkenyl intermediate |
| 07/21/2005 | US20050159473 3-Substituted oxindole beta3 agonists |
| 07/21/2005 | US20050159470 Histone deacetylase inhibitors |
| 07/21/2005 | US20050159469 HIV protease inhibiting compounds |
| 07/21/2005 | US20050159467 5-Aryltetrazole compounds and uses thereof |
| 07/21/2005 | US20050159456 Method of treating of demyelinating diseases or conditions |
| 07/21/2005 | US20050159455 1,4-dihydropyridine and pyridine compounds as calcium channel blockers |
| 07/21/2005 | US20050159452 Nociceptin analogs |
| 07/21/2005 | US20050159451 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 07/21/2005 | US20050159445 Selective iGluR5 receptor antagonists |
| 07/21/2005 | US20050159443 For example, N-[2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-phenyl]-N-methyl-2-[1-methyl-5-(3-methyl-4-nitro-benzoyl)-1H-pyrrol-2-yl]-acetamide; bradykinin receptor agonists; for treating disorders such as pain, inflammation, asthma and allergy |
| 07/21/2005 | US20050159438 Spirocyclic heterocyclic derivatives and methods of their use |
| 07/21/2005 | US20050159437 Pharmaceutical agents |
| 07/21/2005 | US20050159435 [3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine; selective inhibitors of receptor tyrosine kinases and non-receptor tyrosine kinases (eg: Ick, src, abl) or serine/threonine kinases (e.g.: cyclin dependent kinases); carcinoma |
| 07/21/2005 | US20050159431 Substituted alkyl uracils and thereof |
| 07/21/2005 | US20050159428 Nonpeptide and thus metabolically stable; diagnostic tool; amidation of the 4-carboxyquinoline derivative with a primary benzylamine |
| 07/21/2005 | US20050159427 N-acylsulfonamide apoptosis promoters |
| 07/21/2005 | US20050159426 Novartis drug called Imatinib, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, methanosulfonate; synergistic mixture with a second antineoplastic agent |
| 07/21/2005 | US20050159424 pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or C( .dbd. O)NR6, |
| 07/21/2005 | US20050159422 Inhibitors of akt activity |
| 07/21/2005 | US20050159418 Nitrogen compounds used as xanthine oxidase inhibitors, for prophylaxis of inflammation, reperfusion injuries, gout or inflammatory bowel disorders |
| 07/21/2005 | US20050159416 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 1-[3-(1-Acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methoxy-pyridin-3-yl)-urea |
| 07/21/2005 | US20050159407 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 07/21/2005 | US20050159402 Polyarylcarboxamides useful as lipid lowering agents |
| 07/21/2005 | US20050156753 Digital sound processing system for a vehicle |
| 07/21/2005 | DE10360154A1 New 2-(hetero)aryl-tetrahydroquinoline derivatives and 1,2,3,4-tetrahydro-1,5-naphthyridine derivatives are mitotic motor protein Eg5 inhibitors used as anticancer agents for treating carcinoma or leukemia |
| 07/21/2005 | DE10359026A1 Verfahren zur Herstellung von Tetrahydrogeranylaceton A process for preparing tetrahydrogeranylacetone |
| 07/21/2005 | DE10358814A1 Prolinylarylacetamide Prolinylarylacetamide |
| 07/21/2005 | CA2559888A1 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases |
| 07/21/2005 | CA2552946A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 07/21/2005 | CA2552850A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 07/21/2005 | CA2552726A1 Cathepsin cysteine protease inhibitors |
| 07/21/2005 | CA2549641A1 Mitotic kinesin inhibitors |
| 07/21/2005 | CA2549396A1 Cb1 modulator compounds |
| 07/21/2005 | CA2549330A1 Calcitonin gene related peptide receptor antagonists |
| 07/21/2005 | CA2549089A1 Opioid receptor antagonists |
| 07/21/2005 | CA2548849A1 Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| 07/21/2005 | CA2548039A1 5-fluoro-, chloro- and cyano-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5 |
| 07/21/2005 | CA2546039A1 Novel polymorphs of racemic, dextrorotatory, and levorotatory enantiomers of 1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride and mesylate salts |
| 07/20/2005 | EP1554274A1 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
| 07/20/2005 | EP1554272A1 Benzimidazoles and benzothiazoles as inhibitors of map kinase |
| 07/20/2005 | EP1554271A1 Substituted indoles and their use as hcv inhibitors |
| 07/20/2005 | EP1554269A1 Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
| 07/20/2005 | EP1554268A1 Pyrazole inhibitors of the transforming growth factor |
| 07/20/2005 | EP1554267A1 Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity |
| 07/20/2005 | EP1554262A1 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 07/20/2005 | EP1554260A1 Aryloxyalkylamine derivatives as h3 receptor ligands |
| 07/20/2005 | EP1554259A1 Novel bicyclic inhibitors of hormone sensitive lipase |
| 07/20/2005 | EP1554258A1 5-substituted-2-arylpyrazines as modulators of crf receptors |